Polycyclo Ring System Having At Least Three Cyclos And Having The Hetero Ring As One Of The Cyclos Patents (Class 549/12)
  • Publication number: 20150141666
    Abstract: A bifunctional catalyst for catalyzing both an oxygen reduction reaction and an oxygen evolution reaction is provided, wherein the catalyst comprises a doped graphene backbone having thiol functional groups. A method for producing a bifunctional catalyst is also provided.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Inventors: Zhongwei CHEN, Aiping YU, Fathy Mohamed HASSAN
  • Publication number: 20150045396
    Abstract: The present invention provides a prophylactic or therapeutic agent for giant cell tumors occurring in a bone and soft tissue or for chondrosarcoma, which comprises a non-steroidal anti-inflammatory agent or thiazolidine derivative as an active ingredient, and the like
    Type: Application
    Filed: March 18, 2013
    Publication date: February 12, 2015
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Akihiko Takeuchi, Hiroyuki Tsuchiya
  • Publication number: 20140309437
    Abstract: Process for the preparation of intermediates that are useful in the synthesis of active pharmaceutical ingredients (API), in particular active in the central nervous system.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 16, 2014
    Applicant: DIPHARMA FRANCIS S.R.L.
    Inventors: Marco ARTICO, Emanuele ATTOLINO
  • Publication number: 20140243281
    Abstract: Provided herein are pediatric dosage forms for use in the treatment of a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of the pediatric dosage form comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are said pediatric dosage form for use in the treatment of a pediatric liver disease, for use in decreasing the levels of serum bile acids or hepatic bile acids, for use in the treatment of pruritis, for use in reducing liver enzymes or bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 26, 2012
    Publication date: August 28, 2014
    Applicant: Lumena Pharmaceuticals, Inc.
    Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
  • Patent number: 8741448
    Abstract: Disclosed is a fullerene derivative having a formula of F-Cy, wherein F is an open-cage fullerene, and Cy is a chalcogenyl group. The fullerene derivative can be applied to hydrogen storage material and an optoelectronic device such as an organic light emitting diode (OLED), a solar cell, or an organic thin film transistor (TFT).
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: June 3, 2014
    Assignee: Industrial Technology Research Institute
    Inventors: Chih-Ping Chen, Yeu-Ding Chen, Shih-Ching Chuang, Yu-Wei Lin, Fu-Wei Chan
  • Patent number: 8362464
    Abstract: An organic nanofiber including a gelled organic semiconductor compound. Also disclosed is an organic semiconductor transistor and a method of manufacturing an organic semiconductor transistor.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: January 29, 2013
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Jong-in Hong, Myoung-chul Um, Jung-pyo Hong, Seong-hoon Lee
  • Publication number: 20120305919
    Abstract: Disclosed is a fullerene derivative having a formula of F-Cy, wherein F is an open-cage fullerene, and Cy is a chalcogenyl group. The fullerene derivative can be applied to hydrogen storage material and an optoelectronic device such as an organic light emitting diode (OLED), a solar cell, or an organic thin film transistor (TFT).
    Type: Application
    Filed: August 9, 2011
    Publication date: December 6, 2012
    Inventors: Chih-Ping CHEN, Yeu-Ding Chen, Shih-Ching Chuang, Yu-Wei Lin, Fu-Wei Chan
  • Publication number: 20120238563
    Abstract: This invention concerns novel substituted unsaturated tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonine receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in claim 1.
    Type: Application
    Filed: June 4, 2012
    Publication date: September 20, 2012
    Inventors: Jose Maria CID-NÚÑEZ, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez
  • Publication number: 20120035170
    Abstract: This invention concerns novel substituted unsaturated tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonine receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in claim 1.
    Type: Application
    Filed: August 22, 2011
    Publication date: February 9, 2012
    Inventors: José Maria Núñez, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez
  • Patent number: 8105504
    Abstract: Organic materials which possess outstanding stability to oxidative, thermal or light-induced degradation comprise as stabilizers at least one compound of the formula (I) wherein the general symbols are as defined in claim 1. The compounds of formula I are especially useful as stabilizers for protecting polymers and lubricants against oxidative, thermal or light-induced degradation and as scavengers for oxidized developer in color photographic material.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: January 31, 2012
    Assignee: BASF SE
    Inventors: Michèle Gerster, Peter Nesvadba
  • Publication number: 20110275695
    Abstract: The invention relates to crystalline forms of zotepine hydrochloride, including the crystalline hydrochloride salt of zotepine and two cocrystals of zotepine hydrochloride with benzoic acid. The preparation and characterization of these crystalline forms of zotepine hydrochloride is described. The invention also relates to the therapeutic use of the crystalline forms of zotepine hydrochloride to treat central nervous system disorders and to pharmaceutical compositions containing them.
    Type: Application
    Filed: June 11, 2009
    Publication date: November 10, 2011
    Applicant: BIONEVIA PHARMACEUTICALS, INC.
    Inventors: Isabel Kalofonos, Dimitris Kalofonos, William Martin-Doyle, Jason Hanko, Eric J. Hagen
  • Publication number: 20110224276
    Abstract: Optical isomers of phenylpropionic acid drugs are a mixture having R-type optical isomer and S-type optical isomer at a ratio of 10:1-1:10 by weight, wherein the ratio of 1:1 is excluded. A use of the optical isomers includes that the R-type optical isomer is used for manufacturing anti-inflammatory and analgesic drugs and the mixture having the R-type optical isomer and the S-type optical isomer at a ratio of 10:1-1:10 by weight, wherein the ratio of 1:1 is excluded, is used for manufacturing anti-inflammatory and analgesic drugs. The therapeutic indexes of anti-inflammatory and analgesic drugs of the present optical isomers are all higher than those of the S-type optical isomers and the racemate.
    Type: Application
    Filed: November 20, 2009
    Publication date: September 15, 2011
    Inventors: Tao Wang, Yan Geng, Zonggui Wang, Hongzhang Sun
  • Publication number: 20110144094
    Abstract: This invention concerns novel substituted heterocyclic tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.
    Type: Application
    Filed: February 16, 2011
    Publication date: June 16, 2011
    Inventors: José Maria Cid-Núñez, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez
  • Publication number: 20110077394
    Abstract: Compounds of Formula (1) are disclosed. Cb is a carbocyclic or heterocyclic group having an atom within the cyclic structure selected from C, N, Si, and Cr and singly bound to A. A is CR, COR, CSR, CNR2, CCN, CCONR2, CNO2, CNNAr, CX?, or N. Cr is a chromophore having a substantially planar cyclic structure. The compounds function as nanometer-scale rotary molecular motors powered and controlled by light energy. The design of the molecular motor devices is flexible so that the rotary direction, drive light wavelength, and other physical characteristics can be varied. The compounds can be chemically functionalized to allow it to be integrated into or attached to a variety of structures. The device can be used in applications where mechanical power, positional control, and information encoding are to be generated at the size scale of individual molecules.
    Type: Application
    Filed: June 24, 2004
    Publication date: March 31, 2011
    Inventors: Thomas W. Bell, Joseph I. Cline, Christine R. Cremo, Stephen L. Gillett, John H. Frederick
  • Patent number: 7915249
    Abstract: This invention concerns novel substituted heterocyclic tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: March 29, 2011
    Assignee: Janssen Pharmaceutical NV
    Inventors: José Maria Cid-Núñez, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez
  • Publication number: 20100267796
    Abstract: The present invention provides a therapeutic agent for irritable bowel syndrome which comprises, as an active ingredient, a compound having an adenosine uptake inhibitory activity, a therapeutic agent for irritable bowel syndrome which comprises, as an active ingredient, a tricyclic compound represented by formula (I) [wherein L represents —NHC(?O)— or the like, R1 represents a hydrogen atom, halogen, or the like, X1—X2—X3 represents S—CR7?CR8 (wherein R7 and R8 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like), or the like, Y represents —CH2SO2—, —SO2CH2— or the like, R2 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, or the like] or a pharmaceutically acceptable salt thereof, and the like.
    Type: Application
    Filed: October 26, 2007
    Publication date: October 21, 2010
    Applicant: KYOWA HAKKO KOGYO CO., LTD.
    Inventors: Tsuyoshi Yamagata, Kenji Shibata, Yoichi Nishiya, Takashi Seishi, Takashi Sakuma
  • Patent number: 7799824
    Abstract: Quaternary salt compounds of Formula (I) or pharmaceutically acceptable forms thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: September 21, 2010
    Assignee: OraPharma, Inc.
    Inventors: Bharat Lagu, Michael Wachter
  • Publication number: 20100189762
    Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
    Type: Application
    Filed: December 21, 2009
    Publication date: July 29, 2010
    Applicant: EMORY UNIVERSITY
    Inventor: Jack L. Arbiser
  • Patent number: 7763564
    Abstract: The invention relates to a process for the preparation of a titanium catalyst which process comprises: (a) drying a silica carrier at a temperature of from 300 to 800° C. to obtain a dried carrier; (b) contacting the dried carrier obtained in step (a) with a gas stream containing titanium halide at a temperature in the range from 125° C. lower to 125° C. higher than the drying temperature of step (a) and at a pressure higher than 0.8 bar to obtain an impregnated carrier; (c) calcining the impregnated carrier obtained in step (b) to obtain the titanium catalyst.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: July 27, 2010
    Assignee: Shell Oil Company
    Inventors: Jan Karel Frederik Buijink, Johannes Jacobus Maria Van Vlaanderen
  • Publication number: 20100137599
    Abstract: The present invention relates to a process for the preparation of 1,4-butanediol mononitrate as intermediate for large scale preparation of high purity nitrooxybutyl ester of pharmaceutically active compounds.
    Type: Application
    Filed: June 18, 2008
    Publication date: June 3, 2010
    Applicant: NICOX S.A.
    Inventors: Achim Hack, Gunter Weingarner, Matthias Kramer
  • Publication number: 20090215858
    Abstract: The invention relates to substituted benzo-condensed cycloheptanone derivatives, to methods for producing them, to drugs containing said compounds and to the use of said compounds for producing drugs.
    Type: Application
    Filed: May 17, 2006
    Publication date: August 27, 2009
    Applicant: Gruenenthal GmbH
    Inventors: Claudia Hinze, Robert Frank, Ruth Jostock, Klaus Schiene, Michael Haurand, Hagen-Heinrich Hennies
  • Patent number: 7541131
    Abstract: The invention provides a resist composition for use in the production process of a semiconductor such as IC, in the production of a circuit substrate of liquid crystal, thermal head and the like or in other photofabrication processes, a compound for use in the resist composition and a pattern forming method using the resist composition, which are a resist composition comprising (A) a sulfonium salt represented by the following formula (I); and a pattern forming method using the resist composition: wherein R1 represents an alkyl group or an aryl group, R2 to R9 each independently represents a hydrogen atom or a substituent and may combine with each other to form a ring, Z represents an electron-withdrawing divalent linking group, Xn? represents an n-valent anion, n represents an integer of 1 to 3, and m represents the number of anions necessary for neutralizing the electric charge.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: June 2, 2009
    Assignee: FUJIFILM Corporation
    Inventor: Yasutomo Kawanishi
  • Publication number: 20090105327
    Abstract: The present invention relates to compounds of the formula I in which R1, R2, R3, R4, X and Y have the meanings indicated in the description. These compounds have immunomodulating effects, as well as an inhibiting or regulating effect on the release of IL-1? and/or TNF-?. They can therefore be used for the treatment of diseases associated with a disturbance of the immune system.
    Type: Application
    Filed: May 12, 2006
    Publication date: April 23, 2009
    Applicant: Merckle GMBH
    Inventors: Stefan Laufer, Wolfgang Albrecht, Cornelia Greim, Hans-Guenter Striegel, Karola Tollmann
  • Publication number: 20090058289
    Abstract: The present invention relates to triaylamines which are substituted by defined groups. These compounds can be used for producing organic electroluminescent devices.
    Type: Application
    Filed: March 3, 2007
    Publication date: March 5, 2009
    Applicant: MERCK PATENT GMBH
    Inventors: Philipp Stoessel, Holger Heil, Arne Buesing
  • Publication number: 20080262076
    Abstract: This invention concerns novel substituted tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain with binding affinities towards dopamine receptors, in particular dopamine D2 receptors, towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein all substituents are defined as in Claim 1.
    Type: Application
    Filed: June 16, 2006
    Publication date: October 23, 2008
    Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez
  • Patent number: 7329654
    Abstract: The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: February 12, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ramesh M. Kanojia, Nareshkumar F. Jain, Raymond Ng, Zhihua Sui, Jiayi Xu
  • Patent number: 7312203
    Abstract: The present invention relates to 1-aza-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: December 25, 2007
    Assignee: GlaxoSmithKline istraziva{hacek over (c)}ki Centar Zagreb d.o.o.
    Inventors: Mladen Mercep, Milan Mesic, Dijana Pesic
  • Patent number: 7301705
    Abstract: The alicyclic compound of the present invention has a five- or more membered ring structure having an epithioethylene linkage and/or an epidithioethylene linkage, and has tow or more sulfur atoms in its molecule. Optical materials produced by curing the alicyclic compound or a composition containing the alicyclic compound by polymerization show high refractive index.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: November 27, 2007
    Assignee: Mitsubishi Gas Chemical Company, Inc.
    Inventors: Yuichi Yoshimura, Motoharu Takeuchi, Teruo Kamura
  • Patent number: 7226943
    Abstract: The present invention relates to compounds of formula (I) wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: June 5, 2007
    Assignee: AstraZeneca AB
    Inventors: Ingemar Starke, Mikael Ulf Johan Dahlstrom, David Blomberg
  • Patent number: 7166583
    Abstract: The present invention relates to 1,3-diaza-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumor necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: January 23, 2007
    Assignee: Pliva-Istrazivacki Institut d.o.o.
    Inventors: Mladen Mercep, Milan Mesic, Renata Rupcic, Dijana Pesic
  • Patent number: 7087765
    Abstract: Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: August 8, 2006
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Alan L. Mueller, Scott T. Moe
  • Patent number: 6890715
    Abstract: The present invention provides a class of sensors prepared from at least a first material having a positive temperature coefficient of resistance and a second non-conductive or insulating material compositionally different than the first material that show an increase sensitivity detection limit for polar and non-polar analytes. The sensors have applications in the detection of analytes in the environment, associated with diseases and microorganisms.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: May 10, 2005
    Assignee: The California Institute of Technology
    Inventors: Nathan S. Lewis, Robert H. Grubbs, Gregory Sotzing
  • Patent number: 6858732
    Abstract: Benzodioxino-naphtho[1,2-b]pyran compounds having particularly advantageous photochromic properties, such as, high sensitivity/coloration, two distinct absorption bands in the 430-500 nm range and 520-620 nm range of the visible spectrum may be generally described as a naphthopyran having a central nucleus of the formula: wherein F is a 1,4-benzodioxine ring with its 2,3 positions fused to the i, j, or k faces; and R1 and R2 are the atoms or groups providing photochromic properties to the naphthopyran.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: February 22, 2005
    Assignee: Vision-Ease Lens, Inc.
    Inventors: Xuzhi Qin, J. Thomas Ippoliti
  • Publication number: 20040204478
    Abstract: Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals.
    Type: Application
    Filed: April 23, 2004
    Publication date: October 14, 2004
    Applicant: G.D. Searle & Company
    Inventors: Len F. Lee, Shyamal C. Banerjee, Horng-Chih Huang, Jinglin J. Li, Raymond E. Miller, David B. Reitz, Samuel J. Tremont
  • Publication number: 20040176438
    Abstract: Mono-fluorinated and di-fluorinated benzothiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as well as pharmaceutical compositions containing the same compounds.
    Type: Application
    Filed: December 23, 2003
    Publication date: September 9, 2004
    Applicant: G.D. SEARLE, LLC
    Inventors: Samuel J. Tremont, Kevin J. Koeller
  • Publication number: 20040171670
    Abstract: Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: March 9, 2004
    Publication date: September 2, 2004
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Alan L. Mueller, Scott T. Moe
  • Publication number: 20040127713
    Abstract: Compounds represented by formula (1), 1
    Type: Application
    Filed: December 5, 2003
    Publication date: July 1, 2004
    Applicant: Nippon Suisan Kaisha, Ltd.
    Inventors: Shuji Jinno, Takaaki Okita, Naomi Ohtsuka, Shinya Yamashita, Junichiro Hata, Jiro Takeo
  • Patent number: 6750244
    Abstract: Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: June 15, 2004
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Alan L. Mueller, Scott T. Moe
  • Publication number: 20040082647
    Abstract: Among its several embodiments, the present invention provides an improved process for the preparation of tetrahydrobenzothiepine-1,1-dioxide compounds; the provision of a process for preparing a diastereomeric mixture of tetrahydrobenzothiepine-1,1-dioxide compounds from a single diastereomer of such compounds; the provision of a process for the preparation of 3-bromo-2-substituted propionaldehyde compounds; and the provision of a process for the preparation of 3-thio-2-substituted propionaldehyde compounds.
    Type: Application
    Filed: April 21, 2003
    Publication date: April 29, 2004
    Applicant: G.D. SEARLE, LLC
    Inventors: Kevin A. Babiak, Andrew Carpenter, Shine Chou, Pierre-Jean Colson, Payman Farid, Robert Hett, Christian H. Huber, Kevin J. Koeller, Jon P. Lawson, James Li, Eduardo K. Mar, Lawrence M. Miller, Vladislav Orlovski, James C. Peterson, Mark J. Pozzo, Claire A. Przybyla, Samuel J. Tremont, Jay S. Trivedi, Grace M. Wagner, Gerald A. Weisenburger, Benxin Zhi
  • Patent number: 6723731
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, Ar, X, Q, A, Y and Z are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: April 20, 2004
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Publication number: 20040067872
    Abstract: Mono-fluorinated and di-fluorinated benzothiepine apical sodium co-dependent bile acid transport (ASBT) inhibitors are disclosed together with methods of making the same, methods of using the same to treat hyperlipidemic conditions as well as pharmaceutical compositions containing the same compounds.
    Type: Application
    Filed: November 4, 2002
    Publication date: April 8, 2004
    Applicant: G.D. SEARLE, LLC
    Inventors: Samuel J. Tremont, Kevin J. Koeller
  • Publication number: 20040014803
    Abstract: Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals.
    Type: Application
    Filed: February 8, 2002
    Publication date: January 22, 2004
    Applicant: G.D. Searle & Co.
    Inventors: Len F. Lee, Shyamal C. Banerjee, Horng-Chih Huang, Jinglin J. Li, Raymond E. Miller, David B. Reitz, Samuel J. Tremont
  • Publication number: 20040002492
    Abstract: The application concerns a compound of formula I: 1
    Type: Application
    Filed: February 24, 2003
    Publication date: January 1, 2004
    Applicant: Kudos Pharmaceuticals Ltd
    Inventors: Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Stephen Philip Jackson, Mark James O'Connor, Alan Yin Kai Lau, Xiao-Ling Fan Cockcroft, Ian Timothy Williams Matthews, Keith Allan Menear, Laurent Jean Martin Rigoreau, Marc Geoffery Hummersone, Roger John Griffin
  • Publication number: 20030236406
    Abstract: Among its several embodiments, the present invention provides an improved process for the preparation of tetrahydrobenzothiepine-1,1-dioxide compounds; the provision of a process for preparing a diastereomeric mixture of tetrahydrobenzothiepine-1,1-dioxide compounds from a single diastereomer of such compounds; the provision of a process for the preparation of 3-bromo-2-substituted propionaldehyde compounds; and the provision of a process for the preparation of 3-thio-2-substituted propionaldehyde compounds.
    Type: Application
    Filed: December 23, 2002
    Publication date: December 25, 2003
    Inventors: Kevin A. Babiak, Andrew Carpenter, Shine Chou, Pierre-Jean Colson, Payman Farid, Robert Hett, Christian H. Huber, Kevin J. Koeller, Jon P. Lawson, James Li, Eduardo K. Mar, Lawrence M. Miller, Vladislav Orlovski, James C. Peterson, Mark J. Pozzo, Claire A. Przybyla, Samuel J. Tremont, Jay S. Trivedi, Grace M. Wagner, Gerald A. Weisenburger, Benxin Zhi
  • Publication number: 20030220360
    Abstract: Compounds represented by formula (1), 1
    Type: Application
    Filed: November 12, 2002
    Publication date: November 27, 2003
    Applicant: Nippon Suisan Kaisha, Ltd., a Japan corporation
    Inventors: Shuji Jinno, Takaaki Okita, Naomi Ohtsuka, Shinya Yamashita, Junichiro Hata, Jiro Takeo
  • Publication number: 20030166708
    Abstract: Cyclic substituted aminomethyl compounds of general formula IA and IB, methods for production thereof, intermediates in said production methods, a medicament containing at least one of said cyclic substituted aminomethyl compounds, the use of said cyclic substituted aminomethyl compounds for the production of a medicament, pharmaceutical compositions containing said compounds, and methods for the treatment of pain, incontinence, pruritis, tinnitus aurium and/or diarrhea using said pharmaceutical compositions.
    Type: Application
    Filed: January 10, 2003
    Publication date: September 4, 2003
    Inventors: Oswald Karl Zimmer, Babette-Yvonne Koegel, Wolfgang Werner Alfred Strassburger
  • Publication number: 20030158119
    Abstract: The present invention is directed to a 1,4-benzothiepine 1,1-dioxide compound of formula I 1
    Type: Application
    Filed: August 22, 2002
    Publication date: August 21, 2003
    Inventors: Heiner Glombik, Wendelin Frick, Hans-Ludwig Schafer, Werner Kramer
  • Publication number: 20030153750
    Abstract: The present invention relates to the dibenzoazulene compounds represented by formula I as well as to their pharmaceutical preparations for the inhibition of tumor necrosis factor alpha (TNF-&agr;) and interleukine 1 (IL-1) in mammals at all diseases and conditions where these mediators are excessively secreted. The compounds of the present invention also demonstrate an analgetic action and can be used to relieve pain.
    Type: Application
    Filed: November 18, 2002
    Publication date: August 14, 2003
    Applicant: Pliva farmaceutska industrija, dionicko drustvo
    Inventors: Mladen Mercep, Milan Mesic, Dijana Pesic, Zeljko Zupanovic, Boska Hrvacic
  • Patent number: 6602898
    Abstract: Compounds represented by formula (1), wherein X is, for example, CH, CH2, CHR (wherein R is a lower alkyl group or a substituted lower alkyl group) or CRR′ (wherein R and R′ are the same as the above defined R); Y is, for example, CH, CH2 or C═O; Z is, for example, O, S, S=O or SO2; U is C or N; R1 to R4 are each independently, for example, a hydrogen atom, OR, SR (wherein R is the same as defined above), or an aromatic ring, a substituted aromatic ring or a heterocycle; at least one of R5 and R8 is, for example, OH and the remaining of R5 and R8 are each independently, for example, a hydrogen atom or OH, optical isomers thereof, conjugates thereof or pharmaceutically acceptable salts thereof are provided.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: August 5, 2003
    Assignee: Nippon Suisan Kaisha, Ltd.
    Inventors: Shuji Jinno, Takaaki Okita, Naomi Ohtsuka, Shinya Yamashita, Junichiro Hata, Jiro Takeo
  • Patent number: 6566535
    Abstract: A process for preparing a compound represented by the following formula: wherein each symbol is as defined below, or a salt thereof, characterized by subjecting a compound represented by the following formula: wherein R1 is an electron-attracting group; R2, R3, R4, R5, R6 and R7 are each a hydrogen atom, a halogen atom, an optionally substituted amino group, an optionally substituted hydroxyl group, an optionally substituted thiol group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group, provided that R6 and R7 may be united to form a ring; and R8 is a hydrogen atom or an optionally substituted hydrocarbon group, or a salt thereof, to a ring-closing reaction.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: May 20, 2003
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Tatsuya Ito, Tomomi Ikemoto, Kiminori Tomimatsu